文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

难治性慢性咳嗽和不明原因慢性咳嗽的新见解:一项为期6年的双向队列研究。

New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study.

作者信息

Zhang Mengru, Morice Alyn H, Si Fengli, Zhang Li, Chen Qiang, Wang Shengyuan, Zhu Yiqing, Xu Xianghuai, Yu Li, Qiu Zhongmin

机构信息

Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.

Centre for Clinical Science, Respiratory Medicine, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, East Yorkshire, UK.

出版信息

Allergy Asthma Immunol Res. 2023 Nov;15(6):795-811. doi: 10.4168/aair.2023.15.6.795.


DOI:10.4168/aair.2023.15.6.795
PMID:37957796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10643855/
Abstract

PURPOSE: Only limited studies have depicted the unique features and management of refractory chronic cough (RCC) and unexplained chronic cough (UCC). These led to the initiation of this study, which reported the demographic characteristics, manifestations, and long-term outcomes on a large series of consecutive RCC/UCC patients, providing a guideline-led real-world clinical experience. METHODS: Retrospective baseline information was obtained from Clinical Research Database (January 2016 to May 2021). At least 6 months after the last clinic visit, included subjects were prospectively followed up. RESULTS: Three hundred and sixty-nine RCC and UCC patients (199 females, 53.9%) were analyzed. The median cough duration was 24.0 (12.0-72.0) months. Laryngeal symptoms were reported in 95.9% of the patients. The common triggers for coughing were talking (74.9%), pungent odors (47.3%), eating (45.5%), and cold air (42.8%). RCC was considered in 38.2%, and the remainder of 228 patients had UCC, with an equal sex distribution ( = 0.66). Among the 141 RCCs, 90.8% (128) had refractory reflux cough, which was more responsive to current treatments ( < 0.01). Although most features and test results between RCC and UCC were similar, UCC was more commonly inappropriately treated ( < 0.01). Nineteen (7.7-41.1) months after the final clinic visit, 31.2% still coughed persistently, while 68.8% reported cough improvement or remission. RCC reported more favorable treatment outcomes (including cough improvement, control, and spontaneous remission) than UCC ( < 0.01). Coughs with long duration before the initial cough clinic visit ( < 0.01), frequent urinary incontinence ( < 0.01), and being sensitive to "talking" ( < 0.01) or "cold air" ( < 0.01) were less likely to be solved. CONCLUSIONS: The current treatments only improve cough symptoms in two-thirds of patients. Clinical indicators for treatment failure were those coughing for long duration and being sensitive to "talking" or "cold air."

摘要

目的:仅有有限的研究描述了难治性慢性咳嗽(RCC)和不明原因慢性咳嗽(UCC)的独特特征及管理方法。这些研究促使开展本项研究,该研究报告了一大系列连续的RCC/UCC患者的人口统计学特征、临床表现及长期结局,提供了以指南为导向的真实世界临床经验。 方法:从临床研究数据库(2016年1月至2021年5月)获取回顾性基线信息。在最后一次门诊就诊至少6个月后,对纳入的受试者进行前瞻性随访。 结果:分析了369例RCC和UCC患者(199例女性,占53.9%)。咳嗽持续时间的中位数为24.0(12.0 - 72.0)个月。95.9%的患者报告有喉部症状。咳嗽的常见诱发因素为说话(74.9%)、刺激性气味(47.3%)、进食(45.5%)和冷空气(42.8%)。38.2%的患者被诊断为RCC,其余228例患者为UCC,性别分布均衡(P = 0.66)。在141例RCC患者中,90.8%(128例)患有难治性反流性咳嗽,对当前治疗反应更好(P < 0.01)。尽管RCC和UCC之间的大多数特征和检查结果相似,但UCC更常接受不恰当的治疗(P < 0.01)。在最后一次门诊就诊19(7.7 - 41.1)个月后,31.2%的患者仍持续咳嗽,而68.8%的患者报告咳嗽有所改善或缓解。RCC患者报告的治疗效果(包括咳嗽改善、控制和自发缓解)优于UCC(P < 0.01)。初次咳嗽门诊就诊前咳嗽持续时间长(P < 0.01)、频繁尿失禁(P < 0.01)以及对“说话”(P < 0.01)或“冷空气”(P < 0.01)敏感的咳嗽更难治愈。 结论:目前的治疗仅能使三分之二的患者咳嗽症状得到改善。治疗失败的临床指标是咳嗽持续时间长以及对“说话”或“冷空气”敏感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf7/10643855/c7bd381d87b4/aair-15-795-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf7/10643855/474d3b3e6eb8/aair-15-795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf7/10643855/ea4f9369c3c8/aair-15-795-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf7/10643855/c7bd381d87b4/aair-15-795-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf7/10643855/474d3b3e6eb8/aair-15-795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf7/10643855/ea4f9369c3c8/aair-15-795-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf7/10643855/c7bd381d87b4/aair-15-795-g003.jpg

相似文献

[1]
New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study.

Allergy Asthma Immunol Res. 2023-11

[2]
Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis.

Ther Adv Respir Dis. 2024

[3]
Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study.

Ther Adv Respir Dis. 2023

[4]
An observational study to understand burden and cost of care in adults diagnosed with refractory chronic cough (RCC) or unexplained chronic cough (UCC).

Respir Res. 2024-7-4

[5]
Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis.

Appl Health Econ Health Policy. 2023-1

[6]
Is laryngeal hypersensitivity the basis of unexplained or refractory chronic cough?

ERJ Open Res. 2021-3-29

[7]
Characteristics and Management of Patients with Refractory or Unexplained Chronic Cough in Outpatient Hospital Clinics in Spain: A Retrospective Multicenter Study.

Lung. 2023-6

[8]
Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study.

Ther Adv Respir Dis. 2024

[9]
Patient satisfaction with the management of refractory and unexplained chronic cough in Canada: Results from a national survey.

PLoS One. 2024-8-1

[10]
A register-based study: cough - a frequent phenomenon in the adult population.

BMC Pulm Med. 2022-11-19

引用本文的文献

[1]
Efficacy and safety of flupentixol-melitracen in patients with refractory chronic cough: a randomised, double-blinded, placebo-controlled clinical trial.

EClinicalMedicine. 2025-8-4

[2]
ICD-10 Diagnostic Coding Patterns and Clinical Correlates in Refractory Chronic Cough: Analysis from the Korean Chronic Cough Registry.

Lung. 2025-7-20

[3]
Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE).

Am J Respir Crit Care Med. 2025-6

[4]
Efficacy of behavioral cough suppression therapy for refractory chronic cough or unexplained chronic cough: a meta-analysis of randomized controlled trials.

Ther Adv Respir Dis. 2024

[5]
Current opinion in refractory and/or unexplained chronic cough.

Curr Opin Otolaryngol Head Neck Surg. 2024-12-1

本文引用的文献

[1]
The demographics, clinical characteristics and quality of life of patients with chronic cough from the Isala Cough Clinic in the Netherlands.

ERJ Open Res. 2022-12-12

[2]
Prevalence and burden of chronic cough in China: a national cross-sectional study.

ERJ Open Res. 2022-7-25

[3]
Efficacy and safety of gefapixant, a P2X receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.

Lancet. 2022-3-5

[4]
Chronic cough: new insights and future prospects.

Eur Respir Rev. 2021-12-31

[5]
[Chinese expert consensus on the diagnosis and treatment of chronic refractory cough].

Zhonghua Jie He He Hu Xi Za Zhi. 2021-8-12

[6]
Long-Term Treatment Outcomes after Behavioral Speech Therapy for Chronic Refractory Cough.

Lung. 2021-10

[7]
Flupentixol/melitracen for chronic refractory cough after treatment failure with other neuromodulators.

Int J Tuberc Lung Dis. 2021-8-1

[8]
On Chronic Cough Diagnosis, Classification, and Treatment.

Lung. 2021-8

[9]
Differential features of chronic cough according to etiology and the simple decision tree for predicting causes.

Sci Rep. 2021-5-14

[10]
A Comprehensive Analysis of the Stability of Blood Eosinophil Levels.

Ann Am Thorac Soc. 2021-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索